Tyra Biosciences, Inc. (TYRA): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$95.14M

Year ended 2025-12-31

-$109.65M

Trailing 12 months to 2026-06-30

2020-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$95.14M	n/m	2026-03-02, From 2025-01-01
2024-12-31	-$69.77M	n/m	2026-03-02, From 2024-01-01
2023-12-31	-$50.14M	n/m	2025-03-27, From 2023-01-01
2022-12-31	-$50.28M	n/m	2024-03-19, From 2022-01-01
2021-12-31	-$23.75M	n/m	2023-03-22, From 2021-01-01
2020-12-31	-$7.76M	n/a	2022-03-03, From 2020-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Tyra Biosciences, Inc. (TYRA)	2025-12-31	-$95.14M	n/m
Enanta Pharmaceuticals Inc (ENTA)	2025-09-30	-$19.27M	n/m
Zevra Therapeutics, Inc. (ZVRA)	2025-12-31	-$1.60M	n/m
Nektar Therapeutics (NKTR)	2025-12-31	-$208.51M	n/m
Altimmune, Inc. (ALT)	2025-12-31	-$67.53M	n/m
Annexon, Inc. (ANNX)	2025-12-31	-$186.36M	n/m
Tonix Pharmaceuticals Holding Corp. (TNXP)	2025-12-31	-$99.84M	n/m
Neurogene Inc. (NGNE)	2025-12-31	-$77.17M	n/m
Contineum Therapeutics, Inc. (CTNM)	2025-12-31	-$55.31M	n/m

Compare TYRA, ENTA, ZVRA, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗